FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130664242> ?p ?o ?g. }

• W3130664242 endingPage "02" @default.
• W3130664242 startingPage "OT" @default.
• W3130664242 abstract "Abstract Background: Triple negative breast cancer (TNBC) is an aggressive subtype accounting for 15% of all breast cancer cases. It is characterized by larger tumor size, higher grade, early peak of recurrence, and a worse 5-year overall survival rate compared to other breast cancer subtypes. Chemotherapy serves as the backbone for the treatment of metastatic TNBC. Treatment with immunotherapy in combination with Abraxane, a taxane-based chemotherapy, is of benefit only in PD-L1 positive tumors, which represents a minority of the patients. Pelareorep, a proprietary isolate of the unmodified, replication competent reovirus type 3 Dearing (T3D), has been shown to upregulate PD-L1 expression in tumor and inflammatory cells and downregulate intra-tumoral regulatory T-cells in the tumor microenvironment in pre-clinical and early clinical studies. Retifanlimab is a PD-1 inhibitor currently in development. The rationale for this clinical study is that the administration of pelareorep will prime the tumor microenvironment for enhanced tumor response to PD-1 inhibitor retifanlimab.Trial design: This is a phase II multi-site single-arm clinical trial to study the combination of PD-1 inhibitor retifanlimab and the oncolytic virus Pelareorep in metastatic triple negative breast cancer who have progressed on chemotherapy. Eligible patients will receive pelareorep 4.5x1010 TCID50 /day IV, on Days 1, 2, 15 and 16 and retifanlimab 500mg IV on day 3 of every 28-day cycle until disease progression or unacceptable toxicity. Patient will be monitored clinically and radiologically for response to treatment. Tumor tissue, stool and blood samples will be collected while on treatment to evaluate changes in PD-L1 expression, gut microbiome and inflammatory cells induced by the study drugs. (ClinicalTrials.gov Identifier: NCT04445844) Eligibility criteria: Eligible patients will include premenopausal/postmenopausal women with metastatic TNBC who have previously received 1-2 prior lines of chemotherapy in the metastatic setting. ECOG PFS 0-2. Specific aims: Primary endpoint will be objective response rate (ORR) and safety, determined by the number, frequency, duration, and severity of AEs using CTCAE v5.0. The secondary end-points will be progression free survival (PFS), overall survival (OS) and duration of response (DOR) and quality of life measures using EORTC QLQ-C30. Statistical methods: Simon’s optimal 2-stage design will be used to calculate sample size. In the first stage, 14 patients will be accrued. If there are 1 or fewer responses in these 14 patients, the study will be stopped. Otherwise, 11 additional patients will be accrued for a total of 25. The null hypothesis will be rejected if 4 or more responses are observed in 25 patients. The first 6 patients will be enrolled in a staggering interval for the safety run-in phase of the study. Accrual: The study will enroll up to 25 patients at Rutgers Cancer Institute of New Jersey and Ohio State University Comprehensive Cancer Center Contact information: Mridula George, MD Email: mridula@cinj.rutgers.edu Citation Format: Mridula George, Nicole Williams, Maryam Lustberg, Coral Omene, Nancy Chan, Nisha Ohri, Maria Kowzun, Lindsay Potdevin, Firas Eladoumikdachi, Shicha Kumar, Robert Wesolowski, Grey Wilkinson, Danielle Tang, Sinae Kim, Shridar Ganesan, Bruce Haffty, Deborah Toppmeyer. Irene study: Phase 2 study of incmga00012 (retifanlimab)and the oncolytic virus pelareorep in metastatic triple negative breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr OT-32-02." @default.
• W3130664242 created "2021-03-01" @default.
• W3130664242 creator A5008527277 @default.
• W3130664242 creator A5009395077 @default.
• W3130664242 creator A5018355368 @default.
• W3130664242 creator A5030653735 @default.
• W3130664242 creator A5035450321 @default.
• W3130664242 creator A5039385718 @default.
• W3130664242 creator A5044773708 @default.
• W3130664242 creator A5046167207 @default.
• W3130664242 creator A5061989008 @default.
• W3130664242 creator A5063342752 @default.
• W3130664242 creator A5063899863 @default.
• W3130664242 creator A5073661192 @default.
• W3130664242 creator A5078634728 @default.
• W3130664242 creator A5081735541 @default.
• W3130664242 creator A5082312064 @default.
• W3130664242 creator A5086903918 @default.
• W3130664242 creator A5087464264 @default.
• W3130664242 date "2021-02-15" @default.
• W3130664242 modified "2023-09-27" @default.
• W3130664242 title "Abstract OT-32-02: Irene study: Phase 2 study of incmga00012 (retifanlimab)and the oncolytic virus pelareorep in metastatic triple negative breast cancer" @default.
• W3130664242 doi "https://doi.org/10.1158/1538-7445.sabcs20-ot-32-02" @default.
• W3130664242 hasPublicationYear "2021" @default.
• W3130664242 type Work @default.
• W3130664242 sameAs 3130664242 @default.
• W3130664242 citedByCount "1" @default.
• W3130664242 countsByYear W31306642422022 @default.
• W3130664242 crossrefType "journal-article" @default.
• W3130664242 hasAuthorship W3130664242A5008527277 @default.
• W3130664242 hasAuthorship W3130664242A5009395077 @default.
• W3130664242 hasAuthorship W3130664242A5018355368 @default.
• W3130664242 hasAuthorship W3130664242A5030653735 @default.
• W3130664242 hasAuthorship W3130664242A5035450321 @default.
• W3130664242 hasAuthorship W3130664242A5039385718 @default.
• W3130664242 hasAuthorship W3130664242A5044773708 @default.
• W3130664242 hasAuthorship W3130664242A5046167207 @default.
• W3130664242 hasAuthorship W3130664242A5061989008 @default.
• W3130664242 hasAuthorship W3130664242A5063342752 @default.
• W3130664242 hasAuthorship W3130664242A5063899863 @default.
• W3130664242 hasAuthorship W3130664242A5073661192 @default.
• W3130664242 hasAuthorship W3130664242A5078634728 @default.
• W3130664242 hasAuthorship W3130664242A5081735541 @default.
• W3130664242 hasAuthorship W3130664242A5082312064 @default.
• W3130664242 hasAuthorship W3130664242A5086903918 @default.
• W3130664242 hasAuthorship W3130664242A5087464264 @default.
• W3130664242 hasConcept C121608353 @default.
• W3130664242 hasConcept C126322002 @default.
• W3130664242 hasConcept C143998085 @default.
• W3130664242 hasConcept C2775930923 @default.
• W3130664242 hasConcept C2776107976 @default.
• W3130664242 hasConcept C2776694085 @default.
• W3130664242 hasConcept C2777511904 @default.
• W3130664242 hasConcept C2777701055 @default.
• W3130664242 hasConcept C2780110267 @default.
• W3130664242 hasConcept C502942594 @default.
• W3130664242 hasConcept C530470458 @default.
• W3130664242 hasConcept C535046627 @default.
• W3130664242 hasConcept C71924100 @default.
• W3130664242 hasConcept C82210918 @default.
• W3130664242 hasConceptScore W3130664242C121608353 @default.
• W3130664242 hasConceptScore W3130664242C126322002 @default.
• W3130664242 hasConceptScore W3130664242C143998085 @default.
• W3130664242 hasConceptScore W3130664242C2775930923 @default.
• W3130664242 hasConceptScore W3130664242C2776107976 @default.
• W3130664242 hasConceptScore W3130664242C2776694085 @default.
• W3130664242 hasConceptScore W3130664242C2777511904 @default.
• W3130664242 hasConceptScore W3130664242C2777701055 @default.
• W3130664242 hasConceptScore W3130664242C2780110267 @default.
• W3130664242 hasConceptScore W3130664242C502942594 @default.
• W3130664242 hasConceptScore W3130664242C530470458 @default.
• W3130664242 hasConceptScore W3130664242C535046627 @default.
• W3130664242 hasConceptScore W3130664242C71924100 @default.
• W3130664242 hasConceptScore W3130664242C82210918 @default.
• W3130664242 hasIssue "4_Supplement" @default.
• W3130664242 hasLocation W31306642421 @default.
• W3130664242 hasOpenAccess W3130664242 @default.
• W3130664242 hasPrimaryLocation W31306642421 @default.
• W3130664242 hasRelatedWork W1966468630 @default.
• W3130664242 hasRelatedWork W2020150632 @default.
• W3130664242 hasRelatedWork W2034849620 @default.
• W3130664242 hasRelatedWork W2092771806 @default.
• W3130664242 hasRelatedWork W2317787856 @default.
• W3130664242 hasRelatedWork W2331329572 @default.
• W3130664242 hasRelatedWork W2534174115 @default.
• W3130664242 hasRelatedWork W2782589310 @default.
• W3130664242 hasRelatedWork W3030794620 @default.
• W3130664242 hasRelatedWork W3183886430 @default.
• W3130664242 hasVolume "81" @default.
• W3130664242 isParatext "false" @default.
• W3130664242 isRetracted "false" @default.
• W3130664242 magId "3130664242" @default.
• W3130664242 workType "article" @default.